Cero Therapeutics Holdings, Inc. announced a new Purchase Agreement on July 11, 2025, allowing the sale of up to $17.49 million of common stock to an institutional investor, following previous agreements totaling $25 million. To date, they have issued 111,273 shares for approximately $7.5 million under prior agreements.